DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-819

Abbott Laboratories
Attention: Jennifer Blosl, Pharm. D.
Regulatory Affairs Specialist
D389, Building AP30
200 Abbott Park Road
Abbott Park, IL 60064-6157

WRITTEN REQUEST
AMENDMENT #1

Dear Dr. Blosl:

Reference is made to your correspondence dated May 9, 2001, requesting changes to FDA's February 22, 2001, Written Request for pediatric studies for paricalcitol injection.

We have reviewed your proposed changes and are amending the below listed sections of the Written Request. All other terms stated in our Written Request issued on February 22, 2001, remain the same.

- *Type of study:* A 12-week, randomized, double-blind, placebo-controlled, multi-center study.

- *Drug-specific safety concerns:* The principal safety concerns are elevated levels of serum calcium and phosphorus and inappropriately low levels of serum iPTH. Drug treatment should be withheld and/or the dose should be reduced if a patient develops hypercalcemia (> 11.0 mg/dL), a Ca X P product > 75, or an iPTH level < 150 pg/mL. To limit exposure to inappropriately high levels of iPTH, patients should be withdrawn from the study if they have 2 consecutive iPTH values >700 pg/mL after 4 weeks of treatment and if this level represents an increase from baseline, regardless of their phosphorus level. An independent external Data Safety Monitoring Board should oversee the conduct of the trial.

Please submit protocols for the above studies to an investigational new drug application (IND) and clearly mark your submission "**PEDIATRIC PROTOCOL SUBMITTED FOR PEDIATRIC EXCLUSIVITY STUDY**" in large font, bolded type at the beginning of the cover letter of the submission. Please notify us as soon as possible if you wish to enter into a written agreement by submitting a proposed written agreement. Clearly mark your submission "**PROPOSED WRITTEN AGREEMENT FOR PEDIATRIC STUDIES**" in large font, bolded type at the beginning of the cover letter of the submission.

Reports of the studies should be submitted as a supplement to an approved NDA with the proposed labeling changes you believe would be warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF PEDIATRIC STUDY REPORTS – PEDIATRIC EXCLUSIVITY DETERMINATION REQUESTED**" in large font, bolded type at the beginning of the cover letter of the submission and include a copy of this letter. Please also send a copy of the cover letter of your submission, via fax (301-594-0183) or messenger, to the Director, Office of Generic Drugs, HFD-600, Metro Park North II, 7500 Standish Place, Rockville, MD 20855-2773.

If you wish to discuss any amendments to this Written Request, please submit proposed changes and the reasons for the proposed changes to your application. Submissions of proposed changes to this request should be clearly marked "**PROPOSED CHANGES IN WRITTEN REQUEST FOR PEDIATRIC STUDIES**" in large font, bolded type at the beginning of the cover letter of the submission. You will be notified in writing if any changes to this Written Request are agreed upon by the Agency.

We hope you will fulfill this pediatric study request. We look forward to working with you on this matter in order to develop additional pediatric information that may produce health benefits in the pediatric population.

If you have any questions, call Randy Hedin, Senior Regulatory Management Officer, at 301-827-6392.

Sincerely yours,

{See appended electronic signature page}

John K. Jenkins, M.D.
Director
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

John Jenkins

1/11/02 04:48:30 PM